Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

In litigation over the past two years, CureVac alleged the BioNTech and Pfizer vaccine for Covid-19 infringed CureVac patents based on its more than two decades of mRNA research. Under terms of the ...

(Reuters) -CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...